Invest in cutting-edge cancer innovation

How we’re changing the future of cancer diagnosis

At Arquer Diagnostics, we are at the forefront of a revolution in cancer diagnosis, helping transform how people are diagnosed and monitored with the disease.

In some cases, 90-95% of those undergoing invasive and often painful procedures are found to not have cancer. That is why there is a need for a fast, painless and highly accurate way to help clinicians decide who may have cancer and need further investigation and who doesn’t.

Using our breakthrough urinary biomarker technology, we have created a range of new generation tests for some of the most common cancers – bladder, endometrial, ovarian and prostate – which are backed by a rigorous and comprehensive clinical trials programme.

The simplicity of our patented technology is its biggest strength. Our tests are accurate, reliable, cost-effective, and can be used universally. We have strong advisory boards – every step we take is guided by clinicians, putting patient’s needs at the forefront of our decision-making. And our dedicated team has proved it can deliver across R&D, product development, clinical trial programmes and robust manufacturing through to distribution and marketing.


If you’re interested in investing and joining us on our journey to transform cancer diagnostics and the lives of patients everywhere, please email us at or call Nadia Whittley on +44 (0) 191 516 6765 to find out more.

Our investors

The following companies are investors in Arquer Diagnostics.

Please click on their logos to visit their websites.